Your shopping cart is currently empty

(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a novel estrogen inhibitor, commonly used in research for various estrogen-dependent conditions, including cyclic mastalgia and gynecomastia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $47 | In Stock | In Stock | |
| 10 mg | $72 | In Stock | In Stock | |
| 25 mg | $129 | In Stock | In Stock | |
| 50 mg | $213 | In Stock | In Stock | |
| 100 mg | $328 | In Stock | In Stock | |
| 200 mg | $493 | - | In Stock | |
| 500 mg | $789 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $52 | In Stock | In Stock |
| Description | (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a novel estrogen inhibitor, commonly used in research for various estrogen-dependent conditions, including cyclic mastalgia and gynecomastia. |
| Targets&IC50 | ER: |
| In vitro | 4-OHT is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes. 4-HT activates on-target modification frequency for intein-Cas9 variants |
| Cell Research | Cell lines: Adult Rat and Mouse Cardiac MyocytesConcentrations: 0, 0.5, 1, 3, 5, and 10 μMIncubation Time: 15-45 minMethod:For sarcomere length measurements, cells are covered in Tyrode's containing 4OHT, allowed to reach 36 ± 1°C, and then stimulated at 0.2 Hz. |
| Animal Research | Animal Models: Sprague-Dawley ratsFormulation: dissolved in 200 μl tricaprylinDosages: 21 mg/kg, 54 μmol/kgAdministration: oral administration |
| Synonyms | Afimoxifene, 4-Hydroxytamoxifen |
| Molecular Weight | 387.51 |
| Formula | C26H29NO2 |
| Cas No. | 68392-35-8 |
| Smiles | CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1 |
| Relative Density. | 1.092 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (154.83 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.16 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.